The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 10:02 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #98. Auxilium Pharmaceuticals Actient Holdings LLC

Acquirer: Auxilium Pharmaceuticals (AUXL)
Acquiree: Actient Holdings LLC
Details: GTCR, a leading private equity firm, announced today it has sold its portfolio company, Actient Holdings LLC ("Actient"), to Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL,Auxilium), a specialty biopharmaceutical company. Headquartered in Lake Forest, Illinois, Actient is a specialty pharmaceutical company focused on developing, acquiring and marketing products that significantly improve patient outcomes.

Auxilium Pharmaceuticals is a biopharmaceutical company with a focus on developing and commercializing products for specialist audiences. Co. has a range of first- and second-line products across multiple indications, including men's healthcare, orthopedics, dermatology and other therapeutic areas. Among other products in the U.S., Co. markets Testim® (testosterone gel) for the topical treatment of hypogonadism; TESTOPEL® (testosterone pellets) a long-acting implantable testosterone replacement therapy product; STENDRA™ (avanafil), an oral erectile dysfunction (ED) therapy; as well as Edex® (alprostadil for injection), an injectable treatment for ED.

Open the AUXL Page at The Online Investor »

Company Name: 
Auxilium Pharmaceuticals Inc
Drugs & Pharmaceuticals

Open the AUXL Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree AUXL Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 98 of 100 Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.